modulation of DNA-repair, antioxidant, and proteasome-related gene clusters
Evidence-based lifestyle interventions, including weight loss and dietary modification, remain the cornerstone of management
Clinical trial data and post-marketing surveillance have documented gastrointestinal complaints in a substantial proportion of patients, with nausea being the most frequent (reported in 1540% of patients depending on the specific agent and dose), followed by vomiting, diarrhoea, constipation, and dyspepsia
Semaglutide and other GLP-1 medications can trigger unexpected changes in how your body regulates temperature, with some patients reporting increased sensitivity to cold
However, the high cost derived from the purification techniques and the high doses required due to the instability of these molecules in vivo are the two most significant points of concern [23]